(July 17, 2023, 3:46 PM EDT) -- SAN FRANCISCO — A California federal jury has found that third-party payers and health insurers did not prove that an HIV patent settlement between Gilead Sciences Inc. and Teva Pharmaceuticals USA Inc. violated the federal antitrust law by including a reverse payment under which Teva delayed making and selling generic versions of the drugs Truvada and Atripla....